CpG reduced factor VIII variants, compositions and methods and uses for treatment of hemostasis disorders
US11168124B2 · kind B2 · utility
0Cited by
1References
41Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 17, 2017 |
| Grant date | Nov 9, 2021 |
| Priority date | — |
| Expiry date | Mar 17, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2750/14145
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
CpG reduced nucleic acid variants encoding FVIII protein and methods of use thereof are disclosed. In particular embodiments, CpG reduced nucleic acid variants encoding FVIII are expressed more efficiently by cells, are secreted at increased levels by cells over wild-type Factor VIII proteins, exhibit enhanced expression and/or activity over wild-type Factor VIII proteins or are packaged more efficiently into viral vectors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.